Moliterno A R, Hankins W D, Spivak J L
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
N Engl J Med. 1998 Feb 26;338(9):572-80. doi: 10.1056/NEJM199802263380903.
The cause of polycythemia vera, which originates from a multipotent hematopoietic progenitor cell, is unknown. Thrombopoietin is a hematopoietic growth factor that regulates the production of multipotent hematopoietic progenitor cells and platelets. To evaluate the possibility that an abnormality in thrombopoietin-mediated signal transduction might be involved in the pathogenesis of polycythemia vera, we examined thrombopoietin-induced tyrosine phosphorylation of proteins and the expression of the thrombopoietin receptor in platelets from patients with the disease.
Platelets were isolated from the blood of patients with polycythemia vera or other chronic myeloproliferative disorders and control subjects. The platelets were exposed to either thrombopoietin or thrombin and then lysed for analysis of tyrosine phosphorylation of platelet proteins and the expression of the proteins by means of immunoblotting. Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryocytes was also assessed.
Thrombopoietin-mediated tyrosine phosphorylation of proteins was impaired in platelets from 20 patients with polycythemia vera and 3 with idiopathic myelofibrosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 with secondary erythrocytosis, 2 with iron-deficiency anemia, 4 with hemochromatosis, or 5 normal subjects. Thrombin-mediated tyrosine phosphorylation of proteins was intact in platelets from patients with polycythemia vera, and the tyrosine kinases and substrates involved in the process were present in normal amounts. However, expression of the platelet thrombopoietin receptor MpI was markedly reduced or absent in 34 of 34 patients with polycythemia vera and in 13 of 14 patients with idiopathic myelofibrosis. Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of MpI or the lack of its expression. In patients with polycythemia vera, reduced expression of MpI by platelets was associated with reduced expression of MpI by megakaryocytes.
Reduced expression of the thrombopoietin receptor MpI is characteristic of polycythemia vera and idiopathic myelofibrosis. The abnormality appears to distinguish polycythemia vera from other-forms of erythrocytosis.
真性红细胞增多症起源于多能造血祖细胞,其病因尚不清楚。血小板生成素是一种造血生长因子,可调节多能造血祖细胞和血小板的生成。为了评估血小板生成素介导的信号转导异常可能参与真性红细胞增多症发病机制的可能性,我们检测了该疾病患者血小板中血小板生成素诱导的蛋白质酪氨酸磷酸化及血小板生成素受体的表达。
从真性红细胞增多症患者、其他慢性骨髓增殖性疾病患者及对照受试者的血液中分离血小板。将血小板暴露于血小板生成素或凝血酶,然后裂解,通过免疫印迹分析血小板蛋白质的酪氨酸磷酸化及蛋白质表达。还评估了血小板和巨核细胞中血小板生成素受体(Mpl)的表达。
20例真性红细胞增多症患者和3例原发性骨髓纤维化患者的血小板中,血小板生成素介导的蛋白质酪氨酸磷酸化受损,但4例原发性血小板增多症患者、3例慢性粒细胞白血病患者、6例继发性红细胞增多症患者、2例缺铁性贫血患者、4例血色素沉着症患者及5名正常受试者的血小板中未受损。真性红细胞增多症患者血小板中凝血酶介导的蛋白质酪氨酸磷酸化正常,该过程中涉及的酪氨酸激酶和底物数量正常。然而,34例真性红细胞增多症患者中的34例以及14例原发性骨髓纤维化患者中的13例,其血小板血小板生成素受体MpI的表达明显降低或缺失。这两种疾病患者中血小板生成素诱导的蛋白质酪氨酸磷酸化受损均与MpI表达明显降低或缺乏表达一致。在真性红细胞增多症患者中,血小板MpI表达降低与巨核细胞MpI表达降低相关。
血小板生成素受体MpI表达降低是真性红细胞增多症和原发性骨髓纤维化的特征。该异常似乎可将真性红细胞增多症与其他形式的红细胞增多症区分开来。